Ractigen Therapeutics Unveils Groundbreaking RNA Therapy Data at WMS 2026
Ractigen Therapeutics Unveils Groundbreaking RNA Therapy Data at WMS 2026
On October 3, 2026, Ractigen Therapeutics presented compelling first-in-human clinical data for their investigational RNA therapeutic, RAG-18, at the 31st Annual Congress of the World Muscle Society (WMS 2026) in Hiroshima, Japan. This significant milestone marks the establishment of clinical proof-of-mechanism for RNA activation (RNAa) in a human monogenic disease.
Clinical Study Overview
The ongoing Phase I trial (NCT07282652) aims to evaluate RAG-18's safety, tolerability, and efficacy in ambulatory boys aged 4-15 years diagnosed with Duchenne Muscular Dystrophy (DMD). DMD is a severe and progressive neuromuscular disorder primarily affecting boys, caused by mutations in the dystrophin gene, leading to serious muscle degeneration.
Key Findings from the Trial
The results discussed during the presentation indicate the ability of a systemically delivered small activating RNA (saRNA) to significantly increase endogenous target protein levels within human skeletal muscle. Key highlights include:
- - Safety Profile: There were no dose-limiting toxicities or serious adverse events reported, highlighting the favorable safety of RAG-18. All adverse events were mild and resolved without intervention.
- - Functional Improvements: Involved participants demonstrated positive trends in motor and pulmonary functions, with notable improvements observed in spirometric parameters and walking distances.
- - Mechanistic Insights: Paired muscle biopsies indicated a remarkable 3.5- to 5.3-fold upregulation of sarcolemmal utrophin, a protein essential for muscle integrity, signaling potential tissue remodeling and functional restoration.
The Significance of Utrophin
Professor Yi Dai, the Principal Investigator, emphasized that utrophin acts as a natural substitute for dystrophin, making it a prime focus for therapeutic strategies across various DMD mutations. The historical challenges in increasing utrophin levels have been primarily technological, not biological. Ractigen's RNAa technology enables the activation of gene expression directly in human muscle, overcoming these barriers.
Expert Commentary
Long-Cheng Li, the CEO of Ractigen, remarked, "This clinical proof-of-mechanism sets the stage for revolutionary advancements in RNA medicine, allowing us to switch on genes for therapeutic benefits." The results affirm RAG-18’s foundation as a potential disease-modifying therapy for a wide range of DMD patients, offering hope to those previously limited by genetic variability.
Next Steps in Development
With Cohort 2 fully enrolled at a dose of 30 mg, Ractigen is keen on accelerating the clinical development of RAG-18. This investigational therapy, delivered via monthly intravenous infusions, is positioned as a promising avenue in the fight against DMD. As the clinical trials continue, Ractigen remains committed to pushing the boundaries of RNA therapeutics, impacting the lives of many affected by this challenging condition.
About Ractigen Therapeutics
Ractigen Therapeutics is a clinical-stage biopharmaceutical firm dedicated to innovating next-generation RNA therapeutics, with a robust pipeline that intends to meet unmet medical needs in neurological diseases and genetic disorders. Their proprietary RNA activation technology, alongside their unique delivery systems, places them at the forefront of advancements in RNA-based therapies, striving to transform patient care through scientific excellence and innovation.
For more information about their ongoing research and updates, visit Ractigen's website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.